MO
Morepen Laboratories Ltd (MOREPENLAB)
₹141.82
Mkt cap
₹6,625 Cr
P/E ratio
56.40
P/B
6.22
Div yield
0.17%
ROE
5.33%
ROCE
8.05%
EPS (TTM)
₹2.51
Book value
₹23
52W range
33–142
Sector
Healthcare
Price history
Previous close
Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products. [1]
NSE MOREPENLABBSE 500288
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthModerate
TechnicalsBullish
52-week range
0.00% from high₹142
₹33+329.11% from low₹142
Current
₹141.82
Prev close
₹135.79
Day
+4.44%
Price performance
1D
+4.44%
1W
+17.49%
1M
+20.75%
3M
+131.77%
6M
+275.09%
1Y
+190.20%
YTD
+237.43%
Financials
Revenue, profit & margin
P/E ratio
56.4×
MOREPENLAB is 63% above the sector median of 34.6×
MOREPENLAB56.4×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 401 | 422 | 445 | 423 | 455 | 438 | 453 | 466 | 425 | 412 | 484 | 485 | 570 | |
| Expenses | 375 | 388 | 394 | 375 | 404 | 394 | 417 | 424 | 401 | 381 | 438 | 460 | 488 | |
| Operating Profit | 26 | 34 | 51 | 48 | 52 | 44 | 36 | 42 | 24 | 31 | 46 | 24 | 83 | |
| OPM % | 7% | 8% | 11% | 11% | 11% | 10% | 8% | 9% | 6% | 7% | 10% | 5% | 14% | |
| Other Income | 2 | 3 | 4 | 4 | 3 | 5 | 5 | 5 | 4 | 30 | 4 | 8 | 5 | |
| Interest | 0 | 0 | 2 | 1 | 1 | 1 | 1 | 5 | 4 | 4 | 4 | 4 | 5 | |
| Depreciation | 8 | 8 | 8 | 10 | 6 | 2 | 5 | 16 | 9 | 11 | 10 | 6 | 8 | |
| Profit before tax | 21 | 29 | 44 | 42 | 48 | 46 | 35 | 26 | 16 | 46 | 35 | 23 | 75 | |
| Tax % | 29% | 26% | 27% | 32% | 25% | 24% | 24% | 21% | 26% | 10% | 22% | 33% | 24% | |
| Net Profit | 15 | 21 | 32 | 29 | 36 | 35 | 27 | 20 | 11 | 41 | 28 | 16 | 56 | |
| EPS in Rs | 0.29 | 0.42 | 0.63 | 0.55 | 0.71 | 0.64 | 0.49 | 0.37 | 0.20 | 0.75 | 0.50 | 0.29 | 1.03 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +11.23% · closed higher next day 1 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 4 Aug '26 |
| Earnings day | +11.23% |
| +1 day | +14.80% |
| +5 days | +6.19% |
| +15 days | +40.19% |
| +30 days | +74.27% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202635.66%Promoter
Promoters35.66%
FIIs1.46%0.13
DIIs1.28%0.03
Public61.59%0.09
Government0.01%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Morepen Labs. | ₹120.90 | 56.42 | 6,625 | 0.17% | 56 | +424.65% | 570 | +34.07% | 8.05% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports15
Concall transcripts59
PPTAug 2026PPTMay 2026PPTFeb 2026PPTNov 2025PPTAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024RECAug 2024TranscriptMay 2024PPTMay 2024RECMay 2024PPTMay 2024TranscriptFeb 2024PPTFeb 2024TranscriptNov 2023PPTNov 2023PPTAug 2023
Credit ratings1
Announcements5
Announcement Under Regulation 30 Of The SEBI (LODR) 7 Sep - First phase capacity expansion completed ahead of schedule; reactor capacity rises535 KL to 614 KL.Announcement under Regulation 30 (LODR)-Newspaper Publication 3 Sep - Newspaper publication for completion of dispatch of the notice of 41st AGM and Annual report for the FY 2025-26Letter To The Members, (No E-Mail Id Registered), Comprising Weblink Of The Annual Report: 2025-26 2 Sep - Morepen Laboratories’ 41st AGM on 26 Sep 2026; proposed ₹0.20 final dividend, record date 19 Sep 2026.Business Responsibility and Sustainability Reporting (BRSR) 2 Sep - Morepen Laboratories filed its FY2025-26 BRSR as part of the annual report.Notice Of 41St Annual General Meeting 2 Sep